The influence of CYP3A5 and ABCB1 genotype on the pharmacokinetics of Prograf and Advagraf.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Pharmacogenomic; Pharmacokinetics
- 09 May 2014 Accrual to date is 29% according to United Kingdom Clinical Research Network.
- 03 May 2014 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2014 According to UK Clinical Trials Register, status changed from active, no longer recruiting to recruiting.